-transparent.png){kind=logo}
The Sézary syndrome is a frequently lethal disease characterized by circulating malignant cells of thymus-derived (T)-cell origin. The capacity of circulating malignant lymphocytes from patients with this syndrome to synthesize immunoglobulins and to function as helper or suppressor cells regulating immunoglobulin synthesis by bone marrow-derived (B) lymphocytes was determined. Peripheral blood lymphocytes from normal individuals had geometric mean immunoglobulin synthetic rates of 4,910 ng for IgM, 1,270 ng for IgA, and 1,625 ng for IgG per 2 X 10(6) cells in culture with pokeweed mitogen for 7 days. Purified normal B cells had geometric mean synthetic rates of 198 ng for IgM, 145 ng for IgA, and 102 ng for IgG. Leukemic cells from patients with the Sézary syndrome produced essentially no immunoglobulins. Adding normal T cells to normal B cells restored their immunoglobin producing capacity. Leukemic cells from four of five patients tested had a similar capacity to help immunoglobulin synthesis by purified normal B cells. Additionally, Sézary cells from one patient studied induced a nearly 10-fold increase in IgA synthesis by lymphocytes from a child with ataxia telangiectasia and selective IgA deficiency. Furthermore, these Sézary cells induced more than a 500-fold increase in IgG and IgA synthesis by lymphocytes from a child with Nezelof's syndrome. When Sézary cells were added to normal unfractionated lymphocytes, they did not suppress immunoglobulin biosynthesis. In addition, unlike the situation observed when large numbers of normal T cells were added to purified B cells, there was no depression of immunoglobulin synthesis at very high malignant T-cell to B-cell ratios. These data support the view that Sézary T cells do not express suppressor cell activity. The results presented in this paper suggest that neoplastic lymphocytes from the majority of patients with the Sézary syndrome originate from a subset of T cells programmed exclusively for helper-like interactions with B cells in their production of immunoglobulin molecules.
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
February 1983,
Clinical immunology and immunopathology,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
September 1983,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
May 2016,
Acta dermato-venereologica,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
April 1983,
The American Journal of dermatopathology,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
February 2008,
The Journal of investigative dermatology,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
September 1978,
Blood,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
September 2013,
Journal of the American Academy of Dermatology,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
August 2019,
Oncotarget,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
January 1982,
Acta dermato-venereologica,
S Broder, and
R L Edelson, and
M A Lutzner, and
D L Nelson, and
R P MacDermott, and
M E Durm, and
C K Goldman, and
B D Meade, and
T A Waldmann
February 1998,
Leukemia & lymphoma,
